Related Experiment Video

Updated: Jul 5, 2026

Implantation Surgery for Abdominal Vagus Nerve Stimulation and Recording Studies in Awake Rats
07:17

Implantation Surgery for Abdominal Vagus Nerve Stimulation and Recording Studies in Awake Rats

Published on: January 19, 2024

Vagus nerve stimulation (VNS) is effective in treating catastrophic 1 epilepsy in very young children

Nelia Zamponi1, Franco Rychlicki, Ludovica Corpaci

  • 1Pediatric Neurology Department, Azienda Ospedaliera-Universitaria, Ospedali Riuniti, Presidio G Salesi, Ancona, Italy. n.zamponi@tin.it

Neurosurgical Review
|May 1, 2008
PubMed

Insights

Vagus nerve stimulation (VNS) effectively controlled seizures in very young children with severe epilepsy. This treatment improved quality of life and developmental milestones, offering a viable option when other treatments fail.

Area of Science:

  • Pediatric Neurology
  • Neurosurgery
  • Epileptology

Background:

  • Catastrophic epilepsy in infants presents significant treatment challenges.
  • Established therapies often prove insufficient for severe pediatric epilepsy cases.

Observation:

  • Six children under 3 years old with severe epilepsy and cognitive impairment received vagus nerve stimulation (VNS).
  • Three patients with life-threatening status epilepticus were implanted during intensive care unit (ICU) admission.
  • The VNS implantation procedure involved a single cervical incision with no observed complications.

Findings:

  • Four out of six children experienced significant and persistent seizure control improvement (60-90%).
  • VNS facilitated early cessation of status epilepticus and discharge from the ICU for affected patients.
  • Improvements in quality of life, parental satisfaction, and some developmental milestones were noted.

Implications:

  • Vagus nerve stimulation (VNS) is a safe and effective treatment option for severe epilepsy in toddlers when resective surgery is not feasible.
  • VNS offers a well-tolerated alternative for infants with catastrophic epilepsy and multiple developmental disabilities.
  • This study supports considering VNS for very young children facing intractable seizures and associated complications.

More Related Videos

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Vagus Nerve Stimulation as a Tool to Induce Plasticity in Pathways Relevant for Extinction Learning11:02

Vagus Nerve Stimulation as a Tool to Induce Plasticity in Pathways Relevant for Extinction Learning

Published on: August 21, 2015

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Seizures ll: Types01:19

Seizures ll: Types

Seizures are sudden bursts of abnormal electrical discharge in the brain that interfere with normal function. They are commonly divided into three groups: focal seizures, generalized seizures, and other types that do not fit neatly into either category.Focal SeizuresFocal seizures begin in a single brain region. When awareness is preserved, they are called focal aware seizures and may cause sensations such as tingling, unusual smells, or flashing lights. When awareness is impaired, they are...
Epilepsy ll: Types01:22

Epilepsy ll: Types

Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...